FDA clears Mauna Kea Technologies NIR miniprobes for use in urology, surgery

The FDA has cleared a line of confocal miniprobes indicated for use in urological and minimally invasive surgical applications.

June 1, 2016

Mauna Kea Technologies (Paris, France) has received FDA clearance for the company's confocal miniprobes indicated for use in urological and minimally invasive surgical applications with the company's near-infrared (NIR) Cellvizio confocal laser endomicroscopy (CLE) platform.

Related: FDA approves laser endomicroscopy system for intraoperative use

Image-guided surgery with intraoperative macroscopic fluorescence systems provides surgeons with enhanced anatomical guidance. The addition of microscopic fluorescence tissue pathological assessment may provide immediate, actionable information that may be used to improve diagnostic potential and further guide surgical treatments. The Cellvizio platform with NIR miniprobes will be compatible and complementary to existing macroscopic NIR endoscopic platforms proposed by a majority of surgical endoscopy manufacturers.

For more information, please visit www.maunakeatech.com.